Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Trevisani

Showing results (131-140 of 208) with videos related to

Pageof 21
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 18, 2018
Development and Validation of a Scoring System That Includes Corrected QT Interval for Risk Analysis of Patients With Cirrhosis and Gastrointestinal BleedingMaurizio Biselli, Annagiulia Gramenzi, Barbara Lenzi, et al.
Cancers|March 28, 2024
Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with SorafenibMaurizio Biselli, Nicola Reggidori, Massimo Iavarone, et al.
Journal of Hepatology|May 21, 2010
Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survivalValentina Santi, Franco Trevisani, Annagiulia Gramenzi, et al.
Journal of Hepatology|January 17, 2012
Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer populationAlessandro Cucchetti, Franco Trevisani, Matteo Cescon, et al.
Transplantation|August 22, 2022
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential TreatmentsFrancesco Tovoli, Dante Pio Pallotta, Vito Sansone, et al.
Hepatology (Baltimore, Md.)|March 12, 2021
Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic ImplicationsMaurizio Baldassarre, Marina Naldi, Giacomo Zaccherini, et al.
European Journal of Gastroenterology & Hepatology|November 24, 2011
Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in ItalyFabio Farinati, Anna Giacomin, Veronica Vanin, et al.
Journal of Viral Hepatitis|January 17, 2025
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral TherapyAmit G Singal, K Rajender Reddy, Massimo Colombo, et al.
Journal of Cancer Research and Clinical Oncology|December 18, 2017
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuationFranco Trevisani, Giovanni Brandi, Francesca Garuti, et al.
The American Journal of Gastroenterology|February 23, 2007
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillanceFranco Trevisani, Giulia Magini, Valentina Santi, et al.
Pageof 21

Showing results (131-140 of 208) with videos related to

Sort By:
Pageof 21
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 18, 2018
Development and Validation of a Scoring System That Includes Corrected QT Interval for Risk Analysis of Patients With Cirrhosis and Gastrointestinal BleedingMaurizio Biselli, Annagiulia Gramenzi, Barbara Lenzi, et al.
Cancers|March 28, 2024
Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with SorafenibMaurizio Biselli, Nicola Reggidori, Massimo Iavarone, et al.
Journal of Hepatology|May 21, 2010
Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survivalValentina Santi, Franco Trevisani, Annagiulia Gramenzi, et al.
Journal of Hepatology|January 17, 2012
Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer populationAlessandro Cucchetti, Franco Trevisani, Matteo Cescon, et al.
Transplantation|August 22, 2022
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential TreatmentsFrancesco Tovoli, Dante Pio Pallotta, Vito Sansone, et al.
Hepatology (Baltimore, Md.)|March 12, 2021
Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic ImplicationsMaurizio Baldassarre, Marina Naldi, Giacomo Zaccherini, et al.
European Journal of Gastroenterology & Hepatology|November 24, 2011
Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in ItalyFabio Farinati, Anna Giacomin, Veronica Vanin, et al.
Journal of Viral Hepatitis|January 17, 2025
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral TherapyAmit G Singal, K Rajender Reddy, Massimo Colombo, et al.
Journal of Cancer Research and Clinical Oncology|December 18, 2017
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuationFranco Trevisani, Giovanni Brandi, Francesca Garuti, et al.
The American Journal of Gastroenterology|February 23, 2007
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillanceFranco Trevisani, Giulia Magini, Valentina Santi, et al.
Pageof 21